Safety, immunogenicity and reactogenicity of the BNT162b2 and mRNA-1273 COVID-19 vaccines given as two-dose enhancers after two doses of ChAdOx1 nCoV-19 or BNT162b2 and the third dose after BNT162b2 (COV-BOOSTlin, a multifaze):

IgG concentration against SARS-CoV-2 protein, ELU / ml 28 days after the third dose 23,325 (20,030–27,162); 66 25,317 (20,996-30,528); 66 20,502 (16,473-25,517); 35 21,980 (16,476-29,324); 33 26,982 (22,056-33,008); 31 29,161 (23,093-36,823); 33 0 days of the fourth dose 3049 (2550–3646); 66 3469 (2730–4407); 66 2532 (1974–3247); 35 2571 (1874–3527); 34 3761 (2959–4780); 31 4769 (3421–6648); 32 14 days after the fourth dose 37,460 (31,996-43,857); 65 54,936 (46,826-64,452); 67 33,316 (26,942-41,198); 35 52,080 (41,163-65,894); 34 42,949 (34,148-54,019); 30 58,043 (46,693-72,150); 33 Change of route (14 days after the fourth dose). vs. 28 days after the third dose) 1 · 59 (1 · 41–1 · 78); 65 2 · 19 (1 · 90–2 · 52); 66 1 · 62 (1 · 35–1 · 95); 35 2 · 41 (1 · 90–3 · 05); 33 1 · 54 (1 · 35–1 · 76); 30 1 · 99 (1 · 71–2 · 31); 33 Change of route (14 days after the fourth dose). vs. 0 days of the fourth dose) 12 · 19 (10 · 37–14 · 32); 65 15 · 90 (12 · 92–19 · 58); 66 13 · 16 (10 · 24–16 · 91); 35 20 · 26 (15 · 09–27 · 21); 34 11 · 14 (9 · 21–13 · 47); 30 12 · 30 (9 · 39–16 · 11); 32 Cellular response (wild type), clear-forming cells 106 PBMCs

*

For logistical reasons, only 50% of the study sites collected cellular immunology samples (close to an outdoor laboratory) in a basic COV-BOOST study; After the fourth dose, samples of cellular immunology were collected in the immunology cohort.